(Q40568223)

English

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

scientific article published on January 2003

In more languages
default for all languages
No label defined

No description defined

Statements

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group (English)
Jan Oliver Staak
Franck Morschhauser
Christoph Driessen
Konrad Muller-Hermelink
Andreas Engert
German Hodgkin Lymphoma Study Group (GHSG)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit